Literature DB >> 21845378

Percutaneous radiofrequency ablation therapy for hepatocellular carcinoma: a proposed new grading system for the ablative margin and prediction of local tumor progression and its validation.

Hiroki Nishikawa1, Tadashi Inuzuka, Haruhiko Takeda, Jun Nakajima, Azusa Sakamoto, Sinichiro Henmi, Fumihiro Matsuda, Yuji Eso, Tetsuro Ishikawa, Sumio Saito, Ryuichi Kita, Toru Kimura, Yukio Osaki.   

Abstract

BACKGROUND: In the present study we classified the radicality of percutaneous radiofrequency thermal ablation (RFA) therapy according to the extent of the ablated margin. We measured the local recurrence rate for each radicality grade to evaluate the significance of the grading system in assessing the therapeutic effectiveness of RFA and predicting local tumor progression.
METHODS: This retrospective study involved 269 patients with solitary hypervascular hepatocellular carcinoma who had undergone RFA. The mean ± SD observation period after RFA, number of treatment sessions, and tumor diameter were 25.7 ± 19.9 months, 1.2 ± 0.5, and 2.1 ± 0.7 cm, respectively. Patients were evaluated using dynamic computed tomography. We classified the radicality of RFA treatment into four grades (R grades: A, B, C, and D) according to the extent of the ablated tumor margin, calculated the post-RFA cumulative local recurrence rate for each R grade, and analyzed the factors (patient characteristics, biochemical data, contiguous vessels, and tumor marker) contributing to local recurrence.
RESULTS: The cumulative local recurrence rates at 3 years were 6.7, 17.6, 55.8, and 82.2% for Grades A, B, C, and D, respectively. Using univariate analysis, R grade, tumor size (> 2 cm), and des-γ-carboxy prothrombin (DCP) (> 200 mA U/mL) were shown to be significant factors contributing to local recurrence. However, using multivariate analysis, only the R grade was found to be a significant independent factor.
CONCLUSIONS: The proposed R grading method is a valid and useful method for assessing treatment efficacy, and for predicting local tumor progression after RFA.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21845378     DOI: 10.1007/s00535-011-0452-4

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  27 in total

1.  Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan.

Authors:  S Arii; Y Yamaoka; S Futagawa; K Inoue; K Kobayashi; M Kojiro; M Makuuchi; Y Nakamura; K Okita; R Yamada
Journal:  Hepatology       Date:  2000-12       Impact factor: 17.425

Review 2.  Loco-regional treatment of hepatocellular carcinoma.

Authors:  Riccardo Lencioni
Journal:  Hepatology       Date:  2010-08       Impact factor: 17.425

Review 3.  Image-guided tumor ablation: standardization of terminology and reporting criteria.

Authors:  S Nahum Goldberg; Clement J Grassi; John F Cardella; J William Charboneau; Gerald D Dodd; Damian E Dupuy; Debra Gervais; Alice R Gillams; Robert A Kane; Fred T Lee; Tito Livraghi; John McGahan; David A Phillips; Hyunchul Rhim; Stuart G Silverman
Journal:  Radiology       Date:  2005-04-21       Impact factor: 11.105

4.  A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma.

Authors:  Shuichiro Shiina; Takuma Teratani; Shuntaro Obi; Shinpei Sato; Ryosuke Tateishi; Tomonori Fujishima; Takashi Ishikawa; Yukihiro Koike; Haruhiko Yoshida; Takao Kawabe; Masao Omata
Journal:  Gastroenterology       Date:  2005-07       Impact factor: 22.682

5.  Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin.

Authors:  Takahide Nakazawa; Shigehiro Kokubu; Akitaka Shibuya; Koji Ono; Masaaki Watanabe; Hisashi Hidaka; Takeshi Tsuchihashi; Katsunori Saigenji
Journal:  AJR Am J Roentgenol       Date:  2007-02       Impact factor: 3.959

6.  Cost-effectiveness of radiofrequency ablation and surgical therapy for small hepatocellular carcinoma of 3cm or less in diameter.

Authors:  Kenji Ikeda; Masahiro Kobayashi; Satoshi Saitoh; Takashi Someya; Tetsuya Hosaka; Hitomi Sezaki; Yoshiyuki Suzuki; Fumitaka Suzuki; Norio Akuta; Yasuji Arase; Hiromitsu Kumada; Masamichi Matsuda; Masaji Hashimoto; Goro Watanabe
Journal:  Hepatol Res       Date:  2005-11-02       Impact factor: 4.288

7.  Radiofrequency ablation of hepatic tumours: effect of post-ablation margin on local tumour progression.

Authors:  Chang-Hsien Liu; Ronald S Arellano; Raul N Uppot; Anthony E Samir; Debra A Gervais; Peter R Mueller
Journal:  Eur Radiol       Date:  2009-09-16       Impact factor: 5.315

8.  Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection.

Authors:  Riccardo A Lencioni; Hans-Peter Allgaier; Dania Cioni; Manfred Olschewski; Peter Deibert; Laura Crocetti; Holger Frings; Joerg Laubenberger; Ina Zuber; Hubert E Blum; Carlo Bartolozzi
Journal:  Radiology       Date:  2003-05-20       Impact factor: 11.105

9.  Hepatocellular carcinoma after transcatheter hepatic arterial embolization. A histopathologic study of 84 resected cases.

Authors:  T Higuchi; M Kikuchi; M Okazaki
Journal:  Cancer       Date:  1994-05-01       Impact factor: 6.860

10.  High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma.

Authors:  Masahiro Kobayashi; Kenji Ikeda; Yusuke Kawamura; Hiromi Yatsuji; Tetsuya Hosaka; Hitomi Sezaki; Norio Akuta; Fumitaka Suzuki; Yoshiyuki Suzuki; Satoshi Saitoh; Yasuji Arase; Hiromitsu Kumada
Journal:  Cancer       Date:  2009-02-01       Impact factor: 6.860

View more
  20 in total

Review 1.  Therapeutic response assessment of RFA for HCC: contrast-enhanced US, CT and MRI.

Authors:  Yasunori Minami; Naoshi Nishida; Masatoshi Kudo
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

2.  Ablative safety margin depicted by fusion imaging with post-treatment contrast-enhanced ultrasound and pre-treatment CECT/CEMRI after radiofrequency ablation for liver cancers.

Authors:  Xiao-Wan Bo; Hui-Xiong Xu; Le-Hang Guo; Li-Ping Sun; Xiao-Long Li; Chong-Ke Zhao; Ya-Ping He; Bo-Ji Liu; Dan-Dan Li; Kun Zhang; Dan Wang
Journal:  Br J Radiol       Date:  2017-07-27       Impact factor: 3.039

3.  Comparison of high-intensity focused ultrasound therapy and radiofrequency ablation for recurrent hepatocellular carcinoma.

Authors:  Hiroki Nishikawa; Yukio Osaki
Journal:  Hepatobiliary Surg Nutr       Date:  2013-06       Impact factor: 7.293

4.  Case-control study of the RFA therapeutic effect of newly developed 4D US and conventional 2D US.

Authors:  Atsunori Kusakabe; Shunsuke Nojiri; Etsuko Iio; Kentaro Matsuura; Noboru Shinkai; Tomokatsu Miyaki; Takashi Joh
Journal:  J Med Ultrason (2001)       Date:  2012-07-31       Impact factor: 1.314

5.  Clinical effectiveness of bipolar radiofrequency ablation for small liver cancers.

Authors:  Yukio Osaki; Kenji Ikeda; Namiki Izumi; Satoyoshi Yamashita; Hiromitsu Kumada; Shinji Hatta; Kiwamu Okita
Journal:  J Gastroenterol       Date:  2012-10-10       Impact factor: 7.527

6.  Local tumour progression after ultrasound-guided microwave ablation of liver malignancies: risk factors analysis of 2529 tumours.

Authors:  Jie Yu; Ping Liang; Xiao-Ling Yu; Zhi-Gang Cheng; Zhi-Yu Han; Meng-Juan Mu; Qin-Ying Li; Yan-Mei Liu
Journal:  Eur Radiol       Date:  2014-11-19       Impact factor: 5.315

7.  Ultrasound-ultrasound image overlay fusion improves real-time control of radiofrequency ablation margin in the treatment of hepatocellular carcinoma.

Authors:  Yasunori Minami; Tomohiro Minami; Satoru Hagiwara; Hiroshi Ida; Kazuomi Ueshima; Naoshi Nishida; Takamichi Murakami; Masatoshi Kudo
Journal:  Eur Radiol       Date:  2017-12-01       Impact factor: 5.315

8.  Radiofrequency Ablation of Hepatic Tumor: Subjective Assessment of the Perilesional Vascular Network on Contrast-Enhanced Computed Tomography Before and After Ablation Can Reliably Predict the Risk of Local Recurrence.

Authors:  Sireesha Yedururi; Silanath Terpenning; Sanjay Gupta; Patricia Fox; Sooyoung Shin Martin; Claudius Conrad; Evelyne M Loyer
Journal:  J Comput Assist Tomogr       Date:  2017 Jul/Aug       Impact factor: 1.826

9.  Radiofrequency ablation for hepatocellular carcinoma: the relationship between a new grading system for the ablative margin and clinical outcomes.

Authors:  Hiroki Nishikawa; Yukio Osaki; Eriko Iguchi; Haruhiko Takeda; Fumihiro Matsuda; Jun Nakajima; Azusa Sakamoto; Keiichi Hatamaru; Sumio Saito; Akihiro Nasu; Ryuichi Kita; Toru Kimura
Journal:  J Gastroenterol       Date:  2012-10-12       Impact factor: 7.527

10.  Ablative margin states by magnetic resonance imaging with ferucarbotran in radiofrequency ablation for hepatocellular carcinoma can predict local tumor progression.

Authors:  Masahiko Koda; Shiho Tokunaga; Kennichi Miyoshi; Manabu Kishina; Yuki Fujise; Jun Kato; Tomomitsu Matono; Yoshikazu Murawaki; Suguru Kakite; Eijiro Yamashita
Journal:  J Gastroenterol       Date:  2013-01-22       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.